Pablo Garcia-Pavia

Learning objectives

• Understand the nature of amyloidosis and its effects on various organs, particularly the heart
• Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
• Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
• Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
• Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
• Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team